The answer, at least for a substantial share of patients, appears to be yes. Individuals who underwent gross total resection, meaning the surgeon removed all visible tumor, experienced a median progression-free survival of 76 months, compared with just 44 months for those who received only a biopsy. More striking still, when the investigators adjusted their analysis for age, tumor grade, and the use of adjuvant therapy, gross total resection stood out as an independent predictor of prolonged progression-free survival, while subtotal resection did not. In other words, in this cohort, the benefit was concentrated in the patients whose tumors were removed completely, a finding that carries real weight for surgical decision-making.

The study’s scale and molecular rigor distinguish it from much of the earlier literature. Before 2016, oligodendroglioma was diagnosed largely on histology, and older datasets inevitably mixed together tumors with very different biology. The 2021 World Health Organization classification resolved this ambiguity by requiring both IDH mutation and 1p/19q co-deletion for the diagnosis, creating a molecularly homogeneous group of tumors known to be unusually sensitive to chemotherapy and radiotherapy. Because prior studies of resection extent often included mixed glioma populations, some researchers had questioned whether maximal surgery truly mattered in oligodendroglioma, or whether the tumors’ chemosensitivity would render the scalpel’s reach irrelevant. This new cohort, drawn entirely from patients with molecularly confirmed disease, directly addresses that uncertainty.

The clinical portrait that emerges from the data is characteristic of the disease. Most patients, 173 of 267 with recorded presentation, came to medical attention because of seizures, a classic first sign of these tumors. The majority of lesions, 128 of 213, showed no contrast enhancement on imaging, reflecting the tumors’ typically indolent behavior, and nearly two-thirds, 170 of 267, arose in the frontal lobe, a location that influences both surgical accessibility and the risk of functional injury. Two hundred seven patients had grade 2 tumors and 70 had grade 3 disease, allowing the investigators to examine whether the value of resection differed across the grade spectrum.

Surgical practice in the cohort was diverse. Among 249 patients with a documented operation, subtotal resection was the most common procedure, performed in 115 cases, or 46.2 percent, followed by gross total resection in 97 cases, or 39.0 percent, and biopsy in 37 cases, or 14.9 percent. Awake craniotomy, in which the patient is roused during surgery so surgeons can map language and motor function in real time, was used in 25 of 173 applicable cases, or 14.5 percent. This technique, long championed for tumors in eloquent brain regions, allows more aggressive removal while safeguarding speech and movement, and its use in this cohort reflects the growing adoption of functional mapping in glioma surgery.

Safety outcomes were a central concern, because any argument for maximal resection collapses if it comes at the cost of neurological harm. Across the cohort, new permanent neurological deficits occurred in 24 of 254 patients, or 9.4 percent. Critically, the analysis found no observed increase in postoperative deficits among patients who underwent gross total resection compared with those who had less extensive surgery. That combination, a survival-linked procedure that does not appear to add measurable neurological risk in experienced hands, is precisely the profile that surgeons hope for when counseling patients about the aggressiveness of a first operation, which is often the single most consequential treatment decision in the disease’s long natural history.

The subgroup analyses added an important nuance. The progression-free survival advantage of gross total resection over biopsy held up among patients with grade 2 tumors, with a p-value of 0.032, but did not reach statistical significance in the smaller grade 3 subgroup, where the p-value was 0.549. The authors and commentators alike caution against over-reading the grade 3 result, which may reflect limited statistical power in a group of only 70 patients rather than a genuine absence of benefit. Still, the finding underscores that the strongest evidence for maximal safe resection currently lies in the lower-grade tumors, which are often diagnosed in young adults facing decades of life with their disease.

Median follow-up in the study was 57 months, with an interquartile range of 20 to 107 months, a window long enough to capture meaningful differences in progression but one that leaves open questions about overall survival, which the abstract does not report as a primary endpoint in this analysis. Progression-free survival matters enormously in oligodendroglioma because every progression typically triggers further surgery, radiation, or chemotherapy, and each intervention carries cumulative cognitive and neurological costs. Delaying the first progression can therefore translate into years of preserved quality of life, particularly in a disease where patients are often working, parenting, and planning careers at the time of diagnosis.

The study arrives amid a rapidly evolving treatment landscape. Molecular classification has already reshaped glioma care, and targeted drugs such as vorasidenib, which inhibits the mutant IDH enzyme, have shown promise in low-grade gliomas, raising the possibility that systemic therapy may one day reduce reliance on surgery. Yet the Johns Hopkins findings suggest that, for now, the extent of the first resection remains a powerful and modifiable prognostic factor. The results also align with a growing body of international work, including recent RANO resect group analyses, that has sought to define resection thresholds and prognostic classifications for IDH-mutant gliomas, moving the field toward standardized, evidence-based surgical goals.

For patients and clinicians, the practical message is one of careful, individualized planning. The data support pursuing gross total resection when it can be achieved safely, particularly in grade 2 tumors, while confirming that subtotal resection, though common, did not independently outperform biopsy in this cohort once other factors were accounted for. The authors emphasize that their study is retrospective and subject to the inherent limitations of such designs, including selection bias in which patients received which operation. Even so, in a disease where molecular definition has finally allowed clean comparisons, the study offers some of the strongest evidence to date that in oligodendroglioma, what the surgeon removes on day one still matters, and it matters without, in this experience, exacting a price in neurological function.

Subject of Research: Extent of surgical resection and postoperative outcomes in molecularly defined oligodendroglioma

Article Title: Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma

Article References: Surgical characteristics and postoperative outcomes in a retrospective cohort study of patients with molecularly defined oligodendroglioma. (n.d.). https://doi.org/10.1007/s11060-026-05800-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05800-3

Keywords: oligodendroglioma, IDH mutation, 1p/19q co-deletion, extent of resection, gross total resection, progression-free survival, neurosurgery, brain tumor, awake craniotomy, WHO classification, glioma, retrospective cohort study